Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment

Journal of Neuro-Oncology

Volumn 86, Issue 2, 2008, Pages 133-141

  Liang, Yu ^a,b   Diehn, Maximilian ^c   Bollen, Andrew W ^a   Israel, Mark A ^d   Gupta, Nalin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b APPLIED BIOSYSTEMS   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Adhesion; Extracellular matrix; Medulloblastoma; Microarray; Type I collagen

Indexed keywords

BETA1 INTEGRIN; COLLAGEN RECEPTOR; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE 6; TRANSCRIPTION FACTOR ER81;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL; CELL ADHESION; CHROMOSOME 7; CHROMOSOME ABERRATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG TARGETING; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; INHIBITION KINETICS; LEPTOMENINX; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SERIAL ANALYSIS OF GENE EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION;

BRAIN; CASE-CONTROL STUDIES; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 7; COLLAGEN; DATABASES, GENETIC; EXTRACELLULAR MATRIX; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN BETA CHAINS; MEDULLOBLASTOMA; MENINGES; NEUROECTODERMAL TUMORS, PRIMITIVE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REFERENCE VALUES; RNA, MESSENGER; SUPRATENTORIAL NEOPLASMS;

EID: 37249086640     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-007-9457-5     Document Type: Article

References (46)

1. Jemal A, Murray T, Samuels A (2003) Cancer Statistics. CA Cancer J Clin 53:5-26
2. Rutkowski S (2006) Current treatment approaches to early childhood medulloblastoma. Expert Rev Neurother 6(8):1211-1221
3. Evans AE, Jenkin RD, Sposto R et al (1990) The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72(4):572-582
4. Packer RJ, Sutton LN, Elterman R et al (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81(5):690-698
5. Zeltzer PM, Boyett JM, Finlay JL et al (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17(3):832-845
6. Marino S (2005) Medulloblastoma: Developmental mechanisms out of control. Trends Mol Med 11(1):17-22
7. MacDonald TJ, Brown KM, LaFleur B et al (2001) Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29(2):143-152
8. Dirks PB, Harris L, Hoffman HJ et al (1996) Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 29(1):75-84
9. Albright AL, Wisoff JH, Zeltzer P et al (1995) Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 22(1):1-7
10. Cohen BH, Zeltzer PM, Boyett JM et al (1995) Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: A Childrens Cancer Group randomized trial. J Clin Oncol 13(7):1687-1696
11. Huber H, Eggert A, Janss AJ et al (2001) Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas. Eur J Cancer 37(16):2064-2072
12. Grotzer MA, Wiewrodt R, Janss AJ et al (2001) High microvessel density in primitive neuroectodermal brain tumors of childhood. Neuropediatrics 32(2):75-79
13. Pomeroy SL, Tamayo P, Gaasenbeek M et al (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415(6870):436-442
14. Russo C, Pellarin M, Tingby O et al (1999) Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86(2):331-339
15. Burnett ME, White EC, Sih S, von Haken MS, Cogen PH (1997) Chromosome arm 17p deletion analysis reveals molecular genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumors of the central nervous system. Cancer Genet Cytogenet 97(1):25-31
16. McCabe MG, Ichimura K, Liu L et al (2006) High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol 65(6):549-561
17. Bayani J, Zielenska M, Marrano P et al (2000) Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg 93(3):437-448
18. Reardon DA, Michalkiewicz E, Boyett JM et al (1997) Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res 57(18):4042-4047
19. Ramaswamy S, Tamayo P, Rifkin R et al (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 98(26):15149-15154
20. Boon K, Osorio EC, Greenhut SF et al (2002) An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A 99(17):11287-11292
21. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW (1995) Serial analysis of gene expression. Science 270(5235):484-487
22. Karsenty G, Park RW (1995) Regulation of type I collagen genes expression. Int Rev Immunol 12(2-4):177-185
23. Karsenty G, de Crombrugghe B (1991) Conservation of binding sites for regulatory factors in the coordinately expressed alpha 1 (I) and alpha 2 (I) collagen promoters. Biochem Biophys Res Commun 177(1):538-544
24. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH (1989) Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 109(2):877-889
25. Wayner EA, Gil SG, Murphy GF, Wilke MS, Carter WG (1993) Epiligrin, a component of epithelial basement membranes, is an adhesive ligand for alpha 3 beta 1 positive T lymphocytes. J Cell Biol 121(5):1141-1152
26. Quackenbush J (2006) Microarray analysis and tumor classification. N Engl J Med 354(23):2463-2472
27. Liang Y, Diehn M, Watson N et al (2005) Gene expression profiling reveals clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 102(16):5814-5819
28. Liang Y, Bollen AW, Nicholas MK, Gupta N (2005) Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas. BMC Clin Pathol 5:6
29. Liang Y, Bollen AW, Aldape KD, Gupta N (2006) Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer 6:97
30. Montesano R, Orci L, Vassalli P (1983) In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97(5 Pt 1):1648-1652
31. Jackson CJ, Jenkins KL (1991) Type I collagen fibrils promote rapid vascular tube formation upon contact with the apical side of cultured endothelium. Exp Cell Res 192(1):319-323
32. Elkin M, Miao HQ, Nagler A et al (2000) Halofuginone: A potent inhibitor of critical steps in angiogenesis progression. Faseb J 14(15):2477-2485
33. Abramovitch R, Dafni H, Neeman M, Nagler A, Pines M (1999) Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1(4):321-329
34. Elkin M, Ariel I, Miao HQ et al (1999) Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 59(16):4111-4118
35. Gross DJ, Reibstein I, Weiss L et al (2003) Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res 9(10 Pt 1):3788-3793
36. White DJ, Puranen S, Johnson MS, Heino J (2004) The collagen receptor subfamily of the integrins. Int J Biochem Cell Biol 36(8):1405-1410
37. Gamble JR, Matthias LJ, Meyer G et al (1993) Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol 121(4):931-943
38. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5(10):816-826
39. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L et al (1996) Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379(6560):91-96
40. Wu C, Dedhar S (2001) Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 155(4):505-510
41. MacDonald TJ, Taga T, Shimada H et al (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48(1):151-157
42. Taga T, Suzuki A, Gonzalez-Gomez I et al (2002) alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98(5):690-697
43. Rutka JT, Giblin J, Dougherty DV et al (1986) An ultrastructural and immunocytochemical analysis of leptomeningeal and meningioma cultures. J Neuropathol Exp Neurol 45(3):285-303
44. Rutka JT (1997) Medulloblastoma. Clin Neurosurg 44:571-585
45. Ozer E, Sarialioglu F, Cetingoz R et al (2004) Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: A pediatric oncology group study. Pathol Res Pract 200(7-8):501-509
46. Chung DH, Lee JI, Kook MC et al (1998) ILK (beta1-integrin-linked protein kinase): A novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour. Virchows Arch 433(2):113-117